KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) Invested Capital (2016 - 2026)

Alnylam Pharmaceuticals filings provide 18 years of Invested Capital readings, the most recent being $1.1 billion for Q1 2026.

  • On a quarterly basis, Invested Capital rose 97.59% to $1.1 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $1.1 billion, a 97.59% increase, with the full-year FY2025 number at $789.2 million, up 390.51% from a year prior.
  • Invested Capital hit $1.1 billion in Q1 2026 for Alnylam Pharmaceuticals, up from $789.2 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $1.1 billion in Q1 2022 to a low of -$408.1 million in Q2 2023.
  • Median Invested Capital over the past 5 years was $32.4 million (2024), compared with a mean of $221.1 million.
  • Biggest five-year swings in Invested Capital: crashed 147.8% in 2023 and later soared 12209.26% in 2025.
  • Alnylam Pharmaceuticals' Invested Capital stood at -$158.2 million in 2022, then tumbled by 39.45% to -$220.6 million in 2023, then soared by 172.92% to $160.9 million in 2024, then surged by 390.51% to $789.2 million in 2025, then soared by 36.27% to $1.1 billion in 2026.
  • The last three reported values for Invested Capital were $1.1 billion (Q1 2026), $789.2 million (Q4 2025), and $355.2 million (Q3 2025) per Business Quant data.